What’s Fueling Merck & Co Inc (MRK) Stock’s -13.64% Loss Below Its 200-Day SMA?
Truist has recently reduced Merck & Co Inc (MRK) stock to Hold rating, as announced on January 8, 2025, according to Finviz. Earlier, on December 20, 2024, BMO Capital Markets had reduced the stock from a Outperform to Market Perform,
StockStory.org on MSN3h
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock DropsGlobal pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion ...
23hon MSN
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...
Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...
The first full week of February brings a packed earnings calendar, featuring major names across sectors. Tech giants Amazon ...
Investors in Merck & Co Inc (Symbol: MRK) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK ...
In what the Union-Tribune described as a “behind-the-scenes real estate competition,” the City Council voted in closed ...
Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds ...
Zacks.com on MSN23h
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab CapvaxiveCommittee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback